Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course

Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course

Background. The use of atypical antipsychotics in schizophrenia contributes to the reduction of psychotic, affective, negative and cognitive disorders.Aims. To evaluate the effectiveness of ziprasidone therapy in patients with schizoaffective disorder and paranoid schizophrenia with episodic course....

Full description

Bibliographic Details
Main Authors:	L. A. Ivanova, O. P. Vorsina, T. A. Eliseeva, K. A. Frolovа, E. V. Sapozhnikova
Format:	Article
Language:	Russian
Published:	Scientific Сentre for Family Health and Human Reproduction Problems 2019-05-01
Series:	Acta Biomedica Scientifica
Subjects:	schizoaffective disorder schizophrenia ziprasidone
Online Access:	https://www.actabiomedica.ru/jour/article/view/2052

Similar Items

Prodrome of Paranoid Schizophrenia with Episodic Type of Course and Schizoaffective Structure of Manifest Episode
by: Alexander S. Bobrov, et al.
Published: (2014-06-01)

Paranoid schizophrenia versus schizoaffective disorder: Neuropsychological aspects
by: Leposavić Ljubica, et al.
Published: (2015-01-01)

Сomparative analysis of social disadaptation and criticality indicators in patients with schizoaffective disorder and paranoid schizophrenia as components of pathopersonological transformations
by: M. Ye. Khomitskyi
Published: (2018-04-01)

Neurophysiological distinction between schizophrenia and schizoaffective disorder
by: Daniel H Mathalon, et al.
Published: (2010-01-01)

An algorithm for the diagnostic differentiation of schizoaffective disorder and other endogenous psychoses with episodic course (schizophrenia and affective disorders)
by: M. Ye. Khomitskyi
Published: (2020-06-01)

The Process People with Schizophrenia or Schizoaffective Disorder Use to Return to or Initialy Secure Eemployment Following Diagnosis
by: Sheets, Willard A.
Published: (2009)

Thought and language disorders in very early onset schizophrenia, schizoaffective disorder and bipolar disorder
by: Telma Pantano, et al.

Differential Diagnosis of Schizophrenia and Schizoaffective Disorder: the Role of Emotional Content of Memories
by: Malahat Amani, et al.
Published: (2018-01-01)

Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
by: Atiqul Haq Mazumder, et al.
Published: (2021-05-01)

Social and Neurocognitive Deficits in Remitted Patients with Schizophrenia, Schizoaffective and Bipolar Disorder
by: Liana Dehelean, et al.
Published: (2021-03-01)

Effects of Metformin on Weight Loss and Metabolic Control in Obese Patients With Schizophrenia and Schizoaffective Disorder: A Randomized Double-Blind Controlled Clinical Trial
by: Mahboubeh Sabaghi, et al.
Published: (2019-12-01)

Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
by: Izabela Fulone, et al.
Published: (2021-05-01)

SCHIZOAFFECTIVE DISORDER WITH MANIC TYPE : A CASE REPORT
by: A.A. Gede Ocha Rama Kharisma Putra
Published: (2014-02-01)

Nonadherence after hospital discharge in patients with schizophrenia or schizoaffective disorder: A six-month naturalistic follow-up study
by: Dulcinea Vega, et al.
Published: (2021-07-01)

Efficacy of ziprasidone and risperidone in treatment of vagrants with schizophrenia
by: Zhan-Hua Li, et al.
Published: (2016-06-01)

The case of inorganic hypersomnia treated with light therapy in the course of schizoaffective disorder
by: Masiak Jolanta, et al.
Published: (2016-03-01)

Ethnic minority inequalities in access to treatments for schizophrenia and schizoaffective disorders: findings from a nationally representative cross-sectional study
by: Jayati Das-Munshi, et al.
Published: (2018-04-01)

Dose-Dependent Efficacy of Aripiprazole in Treating Patients With Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Li Qian, et al.
Published: (2021-08-01)

Examination Of Working Life In Patients With Schizophrenia And Schizoaffective Disorder: A Pilot Study
by: Beyza Nur Kaytaz, et al.
Published: (2017-09-01)

Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder
by: E.R. Bychkov, et al.
Published: (2011-11-01)

A Perspective on a Possible Relation Between the Psychopathology of the Schizophrenia/Schizoaffective Spectrum and Unconjugated Bilirubin: A Longitudinal Protocol Study
by: João Gama Marques, et al.
Published: (2018-04-01)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
by: Sajatovic M, et al.
Published: (2018-06-01)

Pharmacoeconomic comparison of ziprasidone with other atypical oral antipsychotic agents in schizophrenia
by: Andrea Fagiolini, et al.
Published: (2011-11-01)

Representations of the parental family in patients with schizoaffective disorder and schizophrenia
by: Kholmogorova A.B., et al.
Published: (2013-10-01)

Lateral ventricle size, smooth pursuit eye tracking and neuropsychological test performance in chronic schizophrenia
by: Tallman, Karen Shepard
Published: (2010)

Recovery in schizophrenia: related factors in a group of patients followed up for 5 years in a private practice
by: Mustafa Yildiz
Published: (2017-10-01)

Illness Management and Recovery : Implementation and evaluation of a psychosocial program for schizophrenia and schizoaffective disorder
by: Färdig, Rickard
Published: (2012)

Therapy of a schizoaffective disorder as a risk factor of perinatal complications and fetal developmental disorders
by: Janeczko Dominika, et al.
Published: (2019-06-01)

Association of lyme disease and schizoaffective disorder, bipolar type: Is it inflammation mediated?
by: David William Mattingley, et al.
Published: (2015-01-01)

Transtorno esquizoafetivo e doença de Parkinson: uma comorbidade possível? Schizoaffective disorder and Parkinson’s disease: a possible comorbidity?
by: Arthur Kümmer, et al.
Published: (2006-01-01)

Early trauma, attachment experiences and comorbidities in schizophrenia
by: Thalita Gabínio, et al.
Published: (2018-04-01)

Cognitive impairment in patients with a schizoaffective disorder: a comparison with bipolar patients in euthymia
by: Studentkowski G, et al.
Published: (2010-02-01)

Cortical Alpha Activity in Schizoaffective Patients
by: Mahdi Moeini, et al.
Published: (2017-02-01)

Combined Antirelapse Therapy in Patients with Schizoaffective Disorder: A Prospective Cohort Study
by: Zhanna R. Gardanova, et al.
Published: (2016-06-01)

Increased expression of Kalirin-9 in the auditory cortex of schizophrenia subjects: Its role in dendritic pathology
by: Anthony J. Deo, et al.
Published: (2012-02-01)

Evaluation of serum indexes and electrophysiological characteristics after ziprasidone combined with modified electroconvulsive therapy for schizophrenian
by: Hong-Bo Cao, et al.
Published: (2017-06-01)

Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy
by: Khan UA, et al.
Published: (2020-06-01)

The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats
by: Martina von Wilmsdorff, et al.
Published: (2010-01-01)

The effects of therapeutic concentrations of ziprasidone on free thiols and thiobarbituric acid reactive substances levels in human plasma – in vitro studies
by: Anna Dietrich-Muszalska, et al.
Published: (2012-12-01)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
by: Daniel Schöttle, et al.
Published: (2018-11-01)